

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.: 2003-1593A

First Named Inventor : Takashi KOMAI et al.

Title: NOVEL ANTICOAGULANT

Express Mail Label No.:  
U.S.P.T.O.  
10/697878  
103103  
12278

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Small Entity Status is hereby asserted.</p> <p>3. <input checked="" type="checkbox"/> Japanese Specification (preferred arrangement set forth below)           <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to Sequence Listing, a table, or a computer program listing appendix.</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> </p> <p>4. <input type="checkbox"/> Drawing(s) (35 USC 113)           <span style="float: right;">[Total Sheets: ]</span> </p> <p>5. <input checked="" type="checkbox"/> Oath or Declaration           <span style="float: right;">[Total Pages : 3]</span> <ul style="list-style-type: none"> <li>a.1. <input type="checkbox"/> Newly executed (original or copy)</li> <li>a.2. <input checked="" type="checkbox"/> Unexecuted</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))               <span style="float: right;">(for continuation/divisional with Box 18 completed)</span> <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li> </ul> </li> </ul> </p> <p>6. <input type="checkbox"/> Application Data Sheet (see 37 CFR 1.76)</p>	<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer program (Appendix)</p> <p>8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Form</li> <li>b. Specification Sequence Listing on:               <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li> <li>ii. <input type="checkbox"/> Paper</li> </ul> </li> <li>c. <input type="checkbox"/> The paper and computer readable copies are identical</li> </ul> </p>
--	---

**ACCOMPANYING APPLICATION PARTS**

- 9.  Assignment Papers (cover sheet & document(s))
- 10.  37 CFR 3.73(b) Statement (when there is an assignee)
  - Power of Attorney
- 11.  English Translation Document (if applicable)
- 12.  Information Disclosure Statement (IDS)/PTO-1449
  - Copies of IDS Citations
- 13.  Preliminary Amendment
- 14.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- 15.  Certified Copy of Priority Document(s)
  - (if foreign priority is claimed)*
- 16.  Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i).  
Applicant must attach form PTO/SB/35 or its equivalent.
- 17.  Other
  - Cover Letter Accompanying Application Filed Without Executed Declaration Under 37 CFR 1.53(b) and in a Language Other than English Under 37 CFR 1.52(d)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below, and in a preliminary amendment, or in an Application Data Sheet :

Continuation       Divisional       Continuation-in-part (CIP)      of prior application No.

Prior Application Information    Examiner                  Group Art Unit

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference therein. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**

CUSTOMER NO.

**000513**

By:   
Michael R. Davis  
Registration No. 25,134

WENDEROTH, LIND & PONACK, L.L.P.  
2033 "K" Street, N.W., Suite 800  
Washington, D.C. 20006-1021  
Phone:(202) 721-8200  
Fax:(202) 721-8250

October 31, 2003

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Takashi KOMAI et al. :  
Serial No. NEW : **Attn: APPLICATION BRANCH**  
Filed October 31, 2003 : Attorney Docket No. 2003-1593A  
NOVEL ANTICOAGULANT :  
\_\_\_\_\_

**PATENT OFFICE FEE TRANSMITTAL FORM**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

Attached hereto is a check in the amount of \$770.00 to cover Patent Office fees relating to filing the following attached papers:

New application ..... \$770.00


A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Takashi KOMAI et al.

By:

  
Michael R. Davis  
Registration No. 25,134  
Attorney for Applicants

MRD/pth  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
October 31, 2003

[Check No. 58486]   
2003-1593A